TherapeuticsMD (NASDAQ:TXMD) Shares Gap Down to $1.20

Share on StockTwits

TherapeuticsMD Inc (NASDAQ:TXMD)’s share price gapped down before the market opened on Monday . The stock had previously closed at $1.13, but opened at $1.20. TherapeuticsMD shares last traded at $1.17, with a volume of 115,208 shares.

TXMD has been the subject of a number of recent research reports. JPMorgan Chase & Co. downgraded shares of TherapeuticsMD from an “overweight” rating to a “neutral” rating in a research note on Tuesday, May 19th. Stifel Nicolaus increased their price objective on shares of TherapeuticsMD from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, April 16th. Zacks Investment Research downgraded shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Friday, June 5th. BidaskClub downgraded shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research note on Friday, June 19th. Finally, ValuEngine downgraded shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $8.03.

The company has a debt-to-equity ratio of 22.15, a quick ratio of 3.20 and a current ratio of 3.44. The stock’s fifty day moving average price is $1.22 and its 200-day moving average price is $1.66. The company has a market capitalization of $320.58 million, a P/E ratio of -1.64 and a beta of 2.11.

TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Wednesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). The firm had revenue of $12.25 million during the quarter, compared to the consensus estimate of $11.48 million. TherapeuticsMD had a negative net margin of 333.88% and a negative return on equity of 1,170.63%. On average, research analysts predict that TherapeuticsMD Inc will post -0.59 EPS for the current fiscal year.

In related news, CEO Robert G. Finizio purchased 30,000 shares of the stock in a transaction on Friday, June 5th. The shares were purchased at an average cost of $1.15 per share, with a total value of $34,500.00. Following the acquisition, the chief executive officer now directly owns 18,335,964 shares in the company, valued at $21,086,358.60. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 13.76% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. C WorldWide Group Holding A S raised its holdings in TherapeuticsMD by 94.0% in the 1st quarter. C WorldWide Group Holding A S now owns 6,189,834 shares of the company’s stock valued at $6,561,000 after acquiring an additional 3,000,000 shares during the period. State Street Corp raised its holdings in TherapeuticsMD by 17.4% in the 4th quarter. State Street Corp now owns 5,528,827 shares of the company’s stock valued at $13,380,000 after acquiring an additional 820,614 shares during the period. Bamco Inc. NY raised its holdings in TherapeuticsMD by 5.5% in the 4th quarter. Bamco Inc. NY now owns 3,831,500 shares of the company’s stock valued at $9,272,000 after acquiring an additional 200,000 shares during the period. Geode Capital Management LLC raised its holdings in TherapeuticsMD by 10.9% in the 1st quarter. Geode Capital Management LLC now owns 3,343,232 shares of the company’s stock valued at $3,543,000 after acquiring an additional 329,800 shares during the period. Finally, Stifel Financial Corp raised its holdings in TherapeuticsMD by 11.6% in the 4th quarter. Stifel Financial Corp now owns 3,016,412 shares of the company’s stock valued at $7,283,000 after acquiring an additional 313,971 shares during the period. 67.09% of the stock is currently owned by hedge funds and other institutional investors.

About TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

Featured Article: What is a Tariff?

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Two Sigma Investments LP Sells 30,057 Shares of Flexsteel Industries, Inc.
Two Sigma Investments LP Sells 30,057 Shares of Flexsteel Industries, Inc.
Gol Linhas Aereas Inteligentes SA  Shares Acquired by Two Sigma Investments LP
Gol Linhas Aereas Inteligentes SA Shares Acquired by Two Sigma Investments LP
Two Sigma Investments LP Takes $188,000 Position in CHIMERA INVT CO/SH NEW
Two Sigma Investments LP Takes $188,000 Position in CHIMERA INVT CO/SH NEW
Two Sigma Investments LP Invests $183,000 in Proteostasis Therapeutics Inc
Two Sigma Investments LP Invests $183,000 in Proteostasis Therapeutics Inc
78,560 Shares in Aldeyra Therapeutics, Inc  Purchased by Two Sigma Investments LP
78,560 Shares in Aldeyra Therapeutics, Inc Purchased by Two Sigma Investments LP
SB One Bancorp  Shares Sold by Two Sigma Investments LP
SB One Bancorp Shares Sold by Two Sigma Investments LP


 
© 2006-2020 Zolmax.